Bio-Techne CEO exercises 36,500 stock options
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.
To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.
Insider Trade Summary
36,500 shares exercised/converted
Exercise
19 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 36,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 36,500 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 32,088 | $58.66 | $1.88M |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 214,704 contracts for 141,668 underlying shares (Direct);
Common Stock — 53,077 shares (Direct);
Stock Options (Right to Buy) — 307,975 contracts (Direct);
Performance Restricted Stock Units — 140,265 contracts (Direct);
Performance Stock Options (Right to Buy) — 49,826 contracts (Direct);
Restricted Stock Units — 52,441 contracts (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options exercised: 36,500 shares
Exercise price: $47.60/share
Tax-withholding shares: 32,088 shares
+5 more
8 metrics
Options exercised
36,500 shares
Stock options exercised at $47.60 on April 14, 2026
Exercise price
$47.60/share
Conversion price for 36,500 stock options
Tax-withholding shares
32,088 shares
Shares withheld for tax liability at $58.66/share
Tax-withholding price
$58.66/share
Value used for F-code tax-withholding disposition
Shares owned after transaction
53,077 shares
Direct common stock holdings following Form 4 transactions
Largest remaining option grant
115,724 underlying shares
Options at $66.97 expiring August 5, 2027
Long-dated option grant
90,441 underlying shares
Options at $53.60 expiring August 15, 2035
Performance RSUs block
70,708 underlying shares
Performance restricted stock units with zero exercise price
Key Terms
tax-withholding disposition, Stock Option (Right to Buy, Performance Restricted Stock Units, Restricted Stock Units, +1 more
5 terms
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with an exercise price of 47.6000"
Performance Restricted Stock Units financial
"Performance Restricted Stock Units with an exercise price of 0.0000"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Restricted Stock Units representing rights to receive common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIO-TECHNE (TECH) CEO Kim Kelderman do in this Form 4?
Kim Kelderman exercised stock options for 36,500 shares of Bio-Techne common stock at an exercise price of $47.60 per share. These options were fully exercisable and converted into common shares as part of his equity compensation package.
What stock options remain outstanding for the BIO-TECHNE (TECH) CEO after this Form 4?
The derivative holdings show multiple remaining option grants, including 115,724 underlying shares at an exercise price of $66.97 expiring on August 5, 2027. Additional option awards with different exercise prices and expirations also remain unexercised.
Does BIO-TECHNE (TECH) CEO Kim Kelderman hold restricted stock units?
Yes. The filing lists various restricted stock units and performance restricted stock units tied to Bio-Techne common stock, such as 51,261 performance RSUs and 35,354 RSUs, which vest over future dates if service or performance conditions are met.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates